Skip to main content

University of Exeter Medical School

 Neil Chanchlani

Neil Chanchlani

 01392 406813

 RILD Building IBD Pharmacogenetics,3rd floor


University of Exeter Medical School, RILD Building, RD&E Hospital Wonford, Barrack Road, Exeter, EX2 5DW, UK


Neil is a clinical research fellow working with Prof. Tariq Ahmad and Prof. Mike Weedon in the Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group. His PhD focused on mechanisms of anti-TNF treatment failure in adults and children with inflammatory bowel disease. He is also a paediatric doctor in training with an interest in gastroenterology, hepatology, and nutrition, and clinical editor for the BMJ.


2024 - PhD Predicting anti-TNF treatment failure in patients with inflammatory bowel disease, University of Exeter
2020 - MSc Epidemiology, London School of Hygiene and Tropical Medicine
2017 - MRCPCH, Royal College of Paediatrics and Child Health
2013 - MBChB Medicine, University of Birmingham
2009 - BA (Hons) Biomedical and Healthcare Ethics, University of Leeds


Back to top


Journal articles

Bai BYH, Reppell M, Smaoui N, Waring JF, Pivorunas V, Guay H, Lin S, Chanchlani N, Bewshea C, Goodhand JR, et al (2024). Baseline Expression of Immune Gene Modules in Blood is Associated with Primary Response to Anti-TNF Therapy in Crohn's Disease Patients. J Crohns Colitis, 18(3), 431-445. Abstract.  Author URL.
Chanchlani N, Lin S, Bewshea C, Hamilton B, Thomas A, Smith R, Roberts C, Bishara M, Nice R, Lees CW, et al (2024). Mechanisms and management of loss of response to anti-TNF therapy for patients with Crohn's disease: 3-year data from the prospective, multicentre PANTS cohort study. The Lancet Gastroenterology & Hepatology, 9(6), 521-538.
Green Z, Ashton JJ, Rodrigues A, Spray C, Howarth L, Mallikarjuna A, Chanchlani N, Hart J, Bakewell C, Lee KY, et al (2024). Sustained Increase in Pediatric Inflammatory Bowel Disease Incidence Across the South West United Kingdom over the Last 10 Years. Inflamm Bowel Dis Abstract.  Author URL.
Chanchlani N, Lin S, Smith R, Roberts C, Nice R, McDonald TJ, Hamilton B, Bishara M, Bewshea C, Kennedy NA, et al (2023). Pretreatment Vitamin D Concentrations Do Not Predict Therapeutic Outcome to Anti-TNF Therapies in Biologic-Naïve Patients with Active Luminal Crohn’s Disease. Crohn's & Colitis 360, 5(3). Abstract.
Kennedy NA, Janjua M, Chanchlani N, Lin S, Bewshea C, Nice R, McDonald TJ, Auckland C, Harries LW, Davies M, et al (2023). Vaccine escape, increased breakthrough and reinfection in infliximab-treated patients with IBD during the Omicron wave of the SARS-CoV-2 pandemic. Gut, 72(2), 295-305. Abstract.  Author URL.
Lin S, Hannon E, Reppell M, Waring JF, Smaoui N, Pivorunas V, Guay H, Chanchlani N, Bewshea C, Bai BYH, et al (2023). Whole blood DNA methylation changes are associated with anti-TNF drug concentration in patients with Crohn's disease. J Crohns Colitis Abstract.  Author URL.
Chanchlani N, Lin S, Chee D, Hamilton B, Nice R, Arkir Z, Bewshea C, Cipriano B, Derikx LAAP, Dunlop A, et al (2022). Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. J Crohns Colitis, 16(3), 389-397. Abstract.  Author URL.
Lin S, Kennedy NA, Saifuddin A, Sandoval DM, Reynolds CJ, Seoane RC, Kottoor SH, Pieper FP, Lin K-M, Butler DK, et al (2022). Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. Nat Commun, 13(1). Abstract.  Author URL.
Chanchlani N, Lin S, Auth MK, Lee CL, Robbins H, Looi S, Murugesan SV, Riley T, Preston C, Stephenson S, et al (2022). Implications for sequencing of biologic therapy and choice of second <scp>anti‐TNF</scp> in patients with inflammatory bowel disease: results from the <scp>IMmunogenicity</scp> to Second <scp>Anti‐TNF</scp> therapy (<scp>IMSAT</scp>) therapeutic drug monitoring study. Alimentary Pharmacology & Therapeutics, 56(8), 1250-1263. Abstract.
Lin S, Lau LH, Chanchlani N, Kennedy NA, Ng SC (2022). Recent advances in clinical practice: management of inflammatory bowel disease during the COVID-19 pandemic. Gut, 71(7), 1426-1439. Abstract.
Lin S, Chanchlani N, Carbery I, Janjua M, Nice R, McDonald TJ, Bewshea C, Kennedy NA, Ahmad T, Selinger CP, et al (2022). Understanding <scp>anti‐TNF</scp> treatment failure: does serum triiodothyronine‐to‐thyroxine (<scp>T3</scp>/<scp>T4</scp>) ratio predict therapeutic outcome to <scp>anti‐TNF</scp> therapies in biologic‐naïve patients with active luminal Crohn's disease?. Alimentary Pharmacology & Therapeutics, 56(5), 783-793. Abstract.
Chanchlani N, Rack D, Hossain U, Leigh A (2021). 14-month old boy with abrupt-onset petechiae and bruising. Arch Dis Child Educ Pract Ed, 106(1), 35-37.  Author URL.
Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, et al (2021). Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. Gut, 70(5), 865-875. Abstract.
Chanchlani N, Hodes D (2021). Fifteen-minute consultation: Vulval soreness in the prepubertal girl. Arch Dis Child Educ Pract Ed, 106(6), 333-340.  Author URL.
Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, et al (2021). Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. Gut, 70(10), 1884-1893. Abstract.  Author URL.
Chanchlani N, Parke SC, Hart JW (2021). Langerhans cell histiocytosis in a 5-month-old baby. CMAJ, 193(1).  Author URL.
Nice R, Chanchlani N, Green H, Bewshea C, Ahmad T, Goodhand JR, McDonald TJ, Perry MH, Kennedy NA (2021). Validating the positivity thresholds of drug-tolerant anti-infliximab and anti-adalimumab antibody assays. Aliment Pharmacol Ther, 53(1), 128-137. Abstract.  Author URL.
Chanchlani N, Buchanan F, Gill PJ (2020). Addressing the indirect effects of COVID-19 on the health of children and young people. CMAJ, 192(32), E921-E927.  Author URL.
Chanchlani N, Jarvis P, Hart JW, McMillan CH, Moudiotis CR (2020). Adolescent with abdominal pain poorly responsive to analgesia. Archives of disease in childhood - Education & practice edition Abstract.
Lin S, Green HD, Hendy P, Heerasing NM, Chanchlani N, Hamilton B, Walker GJ, Heap GA, Hobart J, Martin RJ, et al (2020). Clinical Features and Genetic Risk of Demyelination Following Anti-TNF Treatment. J Crohns Colitis, 14(12), 1653-1661. Abstract.  Author URL.
Levine A, Chanchlani N, Hussey S, Ziv-Baran T, Escher JC, Amil Dias J, Veres G, Koletzko S, Turner D, Kolho K-L, et al (2020). Complicated Disease and Response to Initial Therapy Predicts Early Surgery in Paediatric Crohn's Disease: Results from the Porto Group GROWTH Study. J Crohns Colitis, 14(1), 71-78. Abstract.  Author URL.
Sazonovs A, Kennedy NA, Moutsianas L, Heap GA, Rice DL, Reppell M, Bewshea CM, Chanchlani N, Walker GJ, Perry MH, et al (2020). HLA-DQA1*05 Carriage Associated with Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients with Crohn's Disease. Gastroenterology, 158(1), 189-199. Abstract.  Author URL.
Hamilton B, Green H, Heerasing N, Hendy P, Moore L, Chanchlani N, Walker G, Bewshea C, Kennedy NA, Ahmad T, et al (2020). Incidence and prevalence of inflammatory bowel disease in Devon, UK. Frontline Gastroenterology, 12(6), 461-470. Abstract.
Chanchlani N, Walters TD, Russell RK (2020). Managing nonspecific abdominal pain in children and young people. Canadian Medical Association Journal, 192(48), E1639-E1640.
Walker GJ, Chanchlani N, Thomas A, Lin S, Moore L, Heerasing NM, Hendy P, Abdelrahim M, Mole S, Perry MH, et al (2020). Primary care faecal calprotectin testing in children with suspected inflammatory bowel disease: a diagnostic accuracy study. Arch Dis Child, 105(10), 957-963. Abstract.  Author URL.
Walker GJ, Lin S, Chanchlani N, Thomas A, Hendy P, Heerasing N, Moore L, Green HD, Chee D, Bewshea C, et al (2020). Quality improvement project identifies factors associated with delay in IBD diagnosis. Alimentary Pharmacology & Therapeutics, 52(3), 471-480. Abstract.
Honap S, Chee D, Chapman TP, Patel M, Kent AJ, Ray S, Sharma E, Kennedy J, Cripps S, Walsh A, et al (2020). Real-world Effectiveness of Tofacitinib for Moderate to Severe Ulcerative Colitis: a Multicentre UK Experience. J Crohns Colitis, 14(10), 1385-1393. Abstract.  Author URL.
Gordon C, Chee D, Hamilton B, Chanchlani N, Heerasing NM, Hendy P, Lin S, Wesley E, Daniels I, Goodhand JR, et al (2020). Root cause analysis to identify missed opportunities for the diagnosis of colorectal cancer in inflammatory bowel disease. JOURNAL OF CROHNS & COLITIS, 14, S273-S275.  Author URL.
Chanchlani N, Reading NG (2019). A middle aged man with back pain and heavy legs. BMJ, 366  Author URL.
Christie D, Chanchlani N, Salehian S (2019). Fever and tachypnoea in a child. BMJ (Online), 365
Chanchlani N, Russell RK (2019). Inflammatory bowel disease in children and adolescents. CMAJ, 191(6).  Author URL.
Bewshea CM, Ahmad T, Kennedy N, Goodhand J, McDonald T, Green H (2019). Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. Lancet Gastroenterology and Hepatology
Kapeller K, Chanchlani N (2019). Tips for the childhood immunisation OSCE. BMJ, 364  Author URL.
Chanchlani N, Mortier K, Williams LJ, Muhammed R, Auth MKH, Cosgrove M, Fagbemi A, Fell J, Chong S, Zamvar V, et al (2018). Use of Infliximab Biosimilar Versus Originator in a Pediatric United Kingdom Inflammatory Bowel Disease Induction Cohort. J Pediatr Gastroenterol Nutr, 67(4), 513-519. Abstract.  Author URL.
Dhanjal S, Green M, Pearce J, Chanchlani N (2017). Better information sharing and reinforcement of facts needed during transition of young people with epilepsy. Epilepsy Behav, 73, 283-284.  Author URL.
Chanchlani N, Reading NG, Goodhand JR (2017). Haemosuccus pancreaticus. BMJ (Online), 356
Chanchlani N, Davis F, Devarajan K (2017). Ongoing vomiting in an infant. BMJ, 357  Author URL.
Wong ML, Chanchlani N, Croft G (2017). Out of place: recognising, understanding and responding to the health needs of looked after refugee and trafficked children and young people – conference report. Adoption and Fostering, 41(1), 91-95.
Wolfe I, Sigfrid L, Chanchlani N, Lenton S (2016). Child Health Systems in the United Kingdom (England). J Pediatr, 177S, S217-S242. Abstract.  Author URL.
Chanchlani N, Harewood C, Hossain U, Leigh A (2015). Better Transition Readiness for Adolescents Begins with Effective Communication. J Pediatr Hematol Oncol, 37(7), 574-575.  Author URL.
Chanchlani N, McGee M, McDonagh JE (2015). Informational continuity is integral for successful transition of adolescents to adult care. J Rheumatol, 42(5), 901-902.  Author URL.
Sandoo A, Chanchlani N, Hodson J, Smith JP, Douglas KM, Kitas GD (2014). The relationship between cardiovascular disease risk prediction scores and vascular function and morphology in rheumatoid arthritis. Clin Exp Rheumatol, 32(6), 914-921. Abstract.  Author URL.
Sandoo A, Chanchlani N, Hodson J, Smith JP, Douglas KM, Kitas GD (2013). Classical cardiovascular disease risk factors associate with vascular function and morphology in rheumatoid arthritis: a six-year prospective study. Arthritis Res Ther, 15(6). Abstract.  Author URL.
Chanchlani N, Neale E, Rylance PB (2012). A South African man with renal failure and pulmonary shadowing. BMJ, 344  Author URL.
Chanchlani N, Godlee F (2012). Educating tomorrow's doctors. BMJ, 344  Author URL.


Chanchlani N, Lin S, Hamilton B, Bewshea C, Thomas A, Smith R, Roberts C, Nice R, McDonald T, Goodhand J, et al (2023). O59 Understanding anti-TNF treatment failure: mechanisms and management of loss of response to anti-TNF therapy, three-year data from the PANTS study. Oral presentations.
Smith R, Lin S, Chanchlani N, Roberts C, Nice R, McDonald TJ, Hamilton B, Bewshea C, Kennedy NA, Goodhand JR, et al (2023). P82 Pre-treatment vitamin D concentrations do not predict therapeutic outcome to anti-TNF therapies in biologic-naïve patients with active luminal Crohn’s disease. Poster presentations.

Back to top

External Engagement and Impact

Back to top

Edit Profile